Review
The Evolving Role of Ferroptosis in Breast Cancer: Translational Implications Present and Future

Hung-Yu Lin 1,2,†, Hui-Wen Ho 2,†, Yen-Hsiang Chang 3,4, Chun-Jui Wei 5,* and Pei-Yi Chu 1,5,6,7,8,*

Citation: Lin, H.-Y.; Ho, H.-W.; Chang, Y.-H.; Wei, C.-J.; Chu, P.-Y. The Evolving Role of Ferroptosis in Breast Cancer: Translational Implications Present and Future. Cancers 2021, 13, 4576. https://doi.org/10.3390/cancers13184576

Academic Editor: Ilana Chefetz
Received: 18 August 2021
Accepted: 10 September 2021
Published: 12 September 2021

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction
Breast cancer (BC) is the most commonly diagnosed cancer among women, and is the fourth leading cause of cancer deaths worldwide, according to a status report on the global cancer burden provided by GLOBOCAN 2020 [1]. To date, the standard treatments for patients with BC include surgery, radiation therapy, hormone therapy, and chemotherapy [2,3]. The cause of death in patients with BC is primarily related to cancer metastasis and relapse, which are associated with metabolic reprogramming that fosters a
corrupted tumor microenvironment (TME) to counteract therapy-induced cell death [4]. Regulated cell death (RCD) is an autonomous and orderly death. In addition to apoptosis and necroptosis, recent studies have revealed new modes of RCD, including pyroptosis and ferroptosis [5–8]. All of these death modes present distinct features in terms of cellular morphology, biochemistry, and signaling pathways (Table 1). Despite decades of extensive study into targeting cancer cell death, such as approaches targeting caspases and BCL-2 families in apoptosis, the clinical implementation of related therapeutic agents remains challenging [9]. Indeed, cancer cells present resistance against apoptotic cellular death [10]. Therefore, targeting a nonapoptotic RCD may offer an alternative path to the development of effective cancer therapeutics.

Apoptosis can be triggered by extrinsic (also known as death receptor-activated) and intrinsic (also known as mitochondrial or BCL-2 regulated) pathways. The extrinsic pathway can be activated by the ligation of tumor necrosis factor receptor (TNFR) superfamily members, which promotes adaptor proteins (e.g., FADD) to activate caspase-8 and then the downstream effector caspase-3 and -7 [11]. The intrinsic pathway can be induced by intrinsic stress (growth factor deprivation, DNA damage, and endoplasmic reticulum stress), and BH3-only proteins (PUMA, NOXA, BIM, BID, BAD) [12,13]. For example, p53-upregulated PUMA can bind with a high affinity to BCL-2, thereby liberating BAX/BAK to the mitochondria. This results in the formation of mitochondrial outer membrane permeabilization (MOMP) and the released cytochrome c binding to APAF-1 to form an apoptosome, leading to apoptosis. Under the induction of endoplasmic reticulum stress, the conformational activation of BAX/BAK acts at the mitochondrial membrane, thereby relaying the signaling for the assembly of the apoptosome [14]. In necroptosis, tumor necrosis factor α (TNFα), the CD95 receptor/Fas ligand complex, and other members of the TNF superfamily were identified as inducers [15]. Receptor-interacting protein kinase 1 (RIPK1), RIPK3 and the mixed lineage kinase domain-like pseudokinase (MLKL) are required proteins for the activation of necroptosis. In response to death receptor activation, the binding of RIPK1 to RIPK3 triggers the formation of necrosomes, resulting in MLKL activation [8]. As a necroptotic effector, the activated MLKL translocates to the plasma membrane, causing permeabilization and subsequent cell death. The predominant hallmarks of pyroptosis are the activation of an inflammasome, a cytosolic multiprotein complex accounting for the release of interleukin-1β (IL-1β) and IL-18, the formation of an apoptosis-associated speck-like protein containing a CARD (ASC), and the activation of proinflammatory caspases [16]. Generally, pattern recognition receptors (PRRs, e.g., nod-like receptor 3 (NLRP3) and absent in melanoma-like receptor 2 (AIM2)) first recognize a variety of dangerous signals, then activate procaspase-1 cleavage and ASC recruitment to assemble inflammasomes. Activated caspase-1 acts to cleave the pyroptosis executor gasdemin D (GSDMD) at the Asp275 site to free the N-terminal domain (GSDMD-NT) and generate nonselective pores on the cell membrane. Meanwhile, caspase-1 cleaves and activates the precursors of IL-1β and IL-18 to produce mature IL-1β and IL-18. The intracellular contents are then released through pores caused by GSDMD-NT, leading to pyroptosis [16]. In addition, an inflammasome-independent, non-canonical pathway mediated by a caspase-1/4/5/11-cleaved GSDMD-NT was recognized [17–19]. Furthermore, caspase-3, an iconic apoptosis-related caspase, was revealed to trigger gasdemin E (GSDME)-dependent pyroptosis under the scenario of chemotherapy drug treatment [20,21]. Ferroptosis is characterized by an iron-dependent manner of RCD, described in detail below. Table 1 summarizes the basic features and representative signaling molecules of the four RCDs.

In terms of anticancer immunity, apoptosis has mainly been considered as tolerogenic cell death (TCD), while some reports suggested that apoptosis is involved in immunogenic cell death (ICD) [15,22]. In contrast, mounting evidence has revealed that ICD can be mediated by the activation of ferroptosis, necroptosis, and pyroptosis [22]. The existence and clarification of the interconnectivity of various RCDs renders growing silver linings for the development of anticancer therapeutics. For example, signatures of pro-ferroptosis, pro-necroptosis, and pro-pyroptosis were reported to be associated with CD8+ T cell infiltration.
across seven common cancers [22]. The sensitivity of the genes involved in ferroptosis, necroptosis and pyroptosis were shown to be positively correlated with microsatellite instability (MSI) and tumor mutation burden (TMB) in a portion of cancers [22]. Therapeutically, clinically approved antitumor drugs that target immunity are reported to induce ICD by way of combined RCDs. For instance, artesunate was shown to simultaneously elicit ferroptosis and necroptosis in cancer cells [23] and exert a potentiation effect on antitumor immunity [24–26]. Doxorubicin was demonstrated to enhance antitumor immunity through the induction of both ferroptosis and pyroptosis. In a mechanistic regard, necroptosis acts to interconnectedly facilitate pyroptosis via activation of the receptor-interacting protein kinase 1 (RIPK1) pathway, which then activates the Nod-like receptor 3 (NLRP3)-caspase-1 pathway [27]. The concomitant induction of ferroptosis and pyroptosis was reported to be mediated by the perturbation of glutathione (GSH) and the activation of gasdermin E (GSDME) in the context of cisplatin exposure [28,29].

In 2012, Dixon et al. first described the concept of ferroptosis [30], which refers to an iron-dependent cell death caused by lipid peroxidation and subsequent plasma membrane rupture [31]. Differing from other types of RCD, ferroptosis does not present the cellular swelling observed in necroptosis and pyroptosis, nor the cellular shrinkage and formation of apoptotic bodies exhibited in apoptosis (Table 1). In terms of organelar morphology, ferroptosis does not exhibit chromatin condensation in the nucleus or cytoskeletal disintegration; it does, however, manifest a distinct disorganization of mitochondria including mitochondrial shrinkage, vanishing of mitochondrial cristae, and rupture of the outer mitochondrial membrane (OMM). A growing body of study has led to the identification of an intricate signaling pathway that controls ferroptosis by inducing iron accumulation and lipid peroxidation or perturbing the antioxidant defensive system. Importantly, recent reports have revealed that cancer cells which are resistant to conventional therapy or harbor a propensity to metastasize are vulnerable to ferroptosis, and that immunotherapeutic effects can be potentiated by ferroptosis [32–35]. In light of this, we herein aimed to review the latest research on ferroptosis to further the understanding of its pathogenesis and to propose new targets for the treatment of BC (Table 2).

Table 1. Characteristics of ferroptosis, apoptosis, necroptosis, and pyroptosis.

| Characteristics | Ferroptosis | Apoptosis | Necroptosis | Pyroptosis |
|-----------------|-------------|-----------|-------------|------------|
| Morphological features | small mitochondria, vanishing mitochondrial cristae | unaltered mitochondria | swollen mitochondria | unaltered mitochondria |
| | OMM rupture | apoptotic bodies | release of cytoplasmic constituents | Pore formation on plasma membrane |
| | normal nucleus | cytoskeletal disintegration | plasma membrane rupture | Inflammasome formation |
| | normal cell size | chromatin condensation | chromatin condensation | Chromatin condensation |
| Biochemical hallmarks | iron accumulation | PS exposure | No PS exposure * | secretion of IL-18 and IL-1β |
| | lipid peroxidation | DNA fragmentation | | |
| Primary immune features | ICD | TCD | ICD | ICD |
| Signaling pathways | TFRC | TNFRSF1A/FADD | TNFRI/RIPIK | release of mtDNA in cytosol |
| | IREB/SLC11A2 | TRAILR1/2 | RIPK1/RIPK3/MLKL | NLRP3/AIM2 |
| | Haem/HO-1 | Caspases-9/-3/-7 | PKC-MAPK-AP-1 | caspase-1/4/5/11/GSDMD |
| | FTH1/FTL/Prominin 2 | PS3/PUMA | caspase-1/ IL-18/IL-1β | caspase-1/4/5/11/GSDMD |
| | NCOA4/ferrotnophagy | BCL-2/BAX/BAK | | |
| | CSD1/2/Fe-S | cytochrome c/ APAF-1 | | |
| | ACSLs/LPCAT3/ALOXs | endoplasmic reticulum | | |
| | GSH/GPx4 | | | |
| | MVA/HMGCR | | | |
| | FSP1/CoQ10 | | | |
| | DHODH1/CaQ10 | | | |

AIM2, absent in melanoma like receptor 2; AP-1, activator protein 1; APAF-1, apoptotic peptidase activating factor 1; BAK, Bcl-2 homologous antagonist/killer; BAX, Bcl-2-associated X; BCL2, B-cell lymphoma 2; FADD, Fas-associated protein with death domain; GSDMD, gasdermin D; GSDME, gasdermin E; ICD, immunogenic cell death; MAPK, mitogen-activated protein kinase; MLKL, mixed lineage kinase domain-like pseudokinase; NLRP3, Nod-like receptor 3; OMM, outer membrane of mitochondria; PKC, protein kinase C; PS, phosphatidylserine; PUMA, p53 upregulated modulator of apoptosis; RIPK1, receptor-interacting protein kinase 1; RIPK3, receptor-interacting protein kinase 3; TCD, tolerogenic cell death; TNFR1, tumor necrosis factor receptor 1; TNFRSF1A, tumor necrosis factor receptor superfamily member 1A; TRAILR, tumor necrosis factor-related apoptosis-inducing ligand receptor-1. * While Annexin V assay remains the most widely used assay for apoptosis detection based on PS exposure, several reports identified this phenomenon in necroptosis as well. Wang et al., in this regard, demonstrated a necroptotic phenotype with an increased PS exposure proportion, activated RIPK1/MLKL axis, and damaged plasma membrane [36].
Table 2. Updated therapeutic approaches for targeting of ferroptotic pathways in BC.

| Target Activators                  | Approaches                      | Phase of Clinical Development | Reference                  |
|-----------------------------------|---------------------------------|------------------------------|-----------------------------|
| Iron activators                   |                                 |                              |                             |
| ↑Transferrin                      | lapatinib                       | in vitro model               | 28827805 [37]              |
| ↑Transferrin                      | lapatinib                       | in vitro model               | 27441659 [38]              |
| ↓SLC40A1                          | lapatinib                       | Marked                       | NCT00667251 [38]           |
| ↑Iron                             | UV light                        | Preclinical animal model     | 32804509 [39]              |
| ↑Iron                             | MOF-Fe^{2+}                     | Preclinical animal model     | 32944722 [40]              |
| ↑Iron                             | Fe_{3}O_{4} nanocapules          | in vitro model               | 34225869 [41]              |
| ↑Iron                             | neratinib                       | Preclinical animal model     | 31409375 [42]              |
| ↑Iron                             | neratinib                       | Marked                       | NCT04366713                |
| ↑Iron                             | Fe^{3+}-PDA NP                  | in vitro model               | 33808898 [43]              |
| ↓CISD1/2, ↑Iron                   | MAD-28                          | Preclinical animal model     | 25762074 [44]              |
| ↑HO-1                             | MI-463                          | in vitro model               | 32945449 [45]              |
| ↑HO-1                             | SGNI                            | Preclinical animal model     | 33827043 [46]              |
| Ferritinophagy activators         |                                 |                              |                             |
| ↑Iron                             | artesunate                      | Phase I trials               | NCT00764036 [47]           |
| Lipid peroxides activators        |                                 |                              |                             |
| ↑ACSL1                            | α-eleostearic acid              | Preclinical animal model     | 33854057 [48]              |
| ↑ACSL4                            | Polyphyllin III                 | Preclinical animal model     | 34040532 [49]              |
| System xc- inhibitors             |                                 |                              |                             |
| ↓SLC7A11                          | Erastin                         | in vitro model               | 33672255 [50]              |
| ↓SLC7A11                          | Lidocaine                       | in vitro model               | 34122108 [51]              |
| ↓SLC7A11                          | miR-106a-5p                     | in vitro model               | 33669597 [52]              |
| ↓SLC7A11                          | sulfasalazine                   | Phase I trials               | NCT03847311                |
| ↓SLC7A11                          | metformin, sulfasalazine        | in vitro model               | 34162423 [53]              |
| ↓SLC7A11                          | 18-β-glycyrrhetinic acid        | in vitro model               | 34271106 [54]              |
| GPX4 pathway inhibitors           |                                 |                              |                             |
| ↓GPX4                             | JQ1+BTZ                         | Preclinical animal model     | 32937365 [55]              |
| ↓NR2                              | overexpression of GSK-3β        | Preclinical animal model     | 32642794 [56]              |
| ↓GPX4                             | RSL-3                           | Preclinical animal model     | 34170581 [57]              |
| ↓GPX4                             | metformin                       | Preclinical animal model     | 33522578 [58]              |
| ↓GPX4                             | DMOCPTL                         | Preclinical animal model     | 33472669 [59]              |
| ↓GPX4, MDM2                        | Compound 3d                     | Preclinical animal model     | 33725632 [60]              |
| ↓TYRO3                            | LDC1267                         | Preclinical animal model     | 33855973 [32]              |
| ↓DHODH                            | leflunomide                     | Preclinical animal model     | 32034120 [61]              |
| ↓DHODH                            | BQR, leflunomide, 4SC-101       | in vitro model               | 28196676 [62]              |
| HMGCR inhibitor                   |                                 |                              |                             |
| ↓HMGCR                            | fluvastatin                     | Phase I trials               | 19728082 [63]              |
| ↓HMGCR                            | atorvastatin                    | Phase II trials              | NCT00816244 [64]           |

↑, promote; ↓, inhibit; ACSL1/4, Acyl-CoA synthetase long chain family members; BQR, brequinar sodium; CISD1/2, CDGSH iron sulfur domain 1/2; DHODH, dihydroorotate dehydrogenase; GPX4, glutathione peroxidase 4; GSK-3β, glycogen synthase kinase 3 beta; HMGCR, HMG-CoA reductase; HO-1, heme oxygenase-1; MDM2, mouse double minute 2; MOP-Fe^{2+}, metal-organic framework-based Fe^{2+} delivery; MI-463, menin-mixed-lineage leukemia (MLL) inhibitor-463; NFR2, nuclear factor, erythroid 2-like 2; PDA NPs, polydopamine nanoparticles; SGNI, Shuganning injection; SLC40A1, solute carrier family 40 member 1; SLC7A11, solute carrier family 7 member 11; TYRO3, tyrosine protein kinase receptor 3.

2. Inducing Ferroptosis by Iron Toxicity and Lipid Peroxides

Iron accumulation and lipid peroxidation are two key hallmarks of ferroptosis [30]. Iron is an important trace element, while an aberrant distribution or content of iron in the body can lead to physiological disorders. Iron imported into a cell can be mediated by serotransferrin through the transferrin receptor (TFRC) (Figure 1) [65]. Iron-loaded serotransferrin-TFRC complexes are internalized through endosomes, where they release...
iron ($\text{Fe}^{2+}$) into the cytoplasm through solute carrier family 11 member 2 (SLC11A2), leading to increased iron accumulation and subsequent induction of ferroptosis [65] (Figure 1). Lactotransferrin and heme provide additional sources of iron through differing import mechanisms in the cell membrane [31]. On the other hand, iron export mediated by solute carrier family 40 member 1 (SLC40A1) inhibits ferroptosis [66]. Knockdown of TFRC can inhibit erastin-induced ferroptosis [67], while heme oxygenase-1 (HO-1) can accelerate erastin-induced ferroptosis by supplementing iron [68]. Ferritin acts as an iron storage protein complex, which is composed of ferritin heavy chain 1 (FTH1) and ferritin light chain (FTL) [69]. Brown et al. reported that prominin-2 acts to form ferritin-containing exosomes, which are exported out of the cell to prevent ferroptosis [70]. As a transcription factor, iron response element binding protein 2 (IREB2) acts to mediate the pro-ferroptosis effect of erastin by increasing expression levels of TFRC and SLC11A2, while decreasing those of SLC40A1, FTH1, and FTL [71]. Ferritinophagy (an autophagic degradation of ferritin), mediated by nuclear receptor coactivator 4 (NCOA4), can enhance intracellular iron ($\text{Fe}^{2+}$) levels and ultimately result in ferroptosis [72,73] (Figure 1). In mitochondria, proteins involved in the utilization of iron for iron-sulfur cluster biogenesis, including cysteine desulfurase (NFS1), iron-sulfur cluster assembly enzyme (ISCU), CDGSH iron sulfur domain 1 (CISD1, also known as mitoNEET), and CISD2 (also known as nutrient-deprivation autophagy factor-1 (NAF-1)), inhibit ferroptosis by increasing the biosynthesis of iron-sulfur clusters (Fe-S), thereby reducing intracellular iron levels [74–77]. Intracellular iron excess can promote subsequent lipid peroxidation by way of at least two mechanisms: (1) the iron-dependent Fenton reaction that produces reactive oxygen species (ROS); and (2) the activation of iron-containing enzymes such as lipoxygenases (ALOXs) [31,78,79]. In the process of ferroptosis, polyunsaturated fatty acids (PUFAs) are most susceptible to lipid peroxidation, which can lead to a damaged membrane structure [80]. Acyl-CoA synthetase long chain family members (ACSLs) and lysophospholipid acyltransferase 3 (LPCAT3) promote the incorporation of polyunsaturated fatty acids (PUFAs) into phospholipids (PLs) to form polyunsaturated fatty acid-containing phospholipids (PUFA-PLs), which are sensitive to ROS-initiated oxidation mediated by ALOXs, leading to the formation of lipid peroxides (PUFA-PL-OOH), and ultimately ferroptosis [81–84] (Figure 1). Zhu et al. have reported that irradiation-activated azobenzene combretastatin A4 (Azo-CA4)-loaded nanocarriers promote the ferroptosis of TNBC cells [39]. A UV light-triggered reduction of Fe$^{3+}$ to Fe$^{2+}$ induces ferroptosis, while the photoisomerization of Azo-CA4 elicits apoptosis. Xu et al. designed a metal–organic framework (MOF)-based Fe$^{2+}$ delivery system to increase intracellular iron toxicity, whereby BC cells and in vivo tumors undergo ferroptosis [40]. Nieto et al. revealed that Fe$^{3+}$-loaded-polydopamine nanoparticles induce ferroptosis by increasing intracellular levels of iron, exerting a synergetic effect on the combination of doxorubicin [43]. Antoniak et al. demonstrated that nanocapsules containing Fe$_3$O$_4$ induce BC cell ferroptosis [41]. Notably, TNBC (MDA-MB-231) cells were more susceptible to Fe$_3$O$_4$ nanocapsules than estrogen receptor (ER)-positive (MCF7) cells. Kato et al. reported that menin-mixed-lineage leukemia inhibitor MI-463 induces ferroptosis in an HO-1 activity-dependent manner [45]. Du et al. have shown that Shuganining injection (SGNI), a traditional Chinese patent medicine, can induce ferroptosis and in vivo tumor growth in TNBC cells by inducing HO-1, which acts to promote intracellular iron accumulation [46]. Ma et al. reported that lapatinib promotes the accumulation of intracellular iron, ROS expression levels, and ultimately ferroptosis by increasing expression levels of transferrin and decreasing SLC40A1 (also known as ferroportin-1) [37,38]. Nagpal et al. revealed that neratinib induces ferroptosis by increasing intracellular iron levels [42]. Induced ferritinophagy has been reported to mediate ferroptosis and the antitumor effect of artemisinins [85–87], which are derived from the Chinese herb Artemisia annua, categorized as a class of antimalarial drugs [88]. An artemisinin derivative, artesunate, was demonstrated as being safe and well-tolerated at an oral dose of up to 200 mg when applied to patients with metastatic BC (NCT00764036; completed phase I clinical trial) [47]. Bai et al. revealed that a derivative of mitocan (small molecules selectively targeting mi-
Iron metabolism and lipid peroxides in ferroptosis. Ferroptosis is primarily triggered by iron accumulation-mediated lipid peroxidation, which is determined by key factors contributing to the import, export, and metabolism of iron and the formation of PUFA-PL-OOH. Serotransferrin-TFRC complexes load iron and facilitate its import through endosome internalization, by which iron can be released via SLC11A2. IREB2 transcriptional activity, heme/HO-1, and lactotransferrin provide additional routes of intracellular iron import. DFO acts as a scavenger of intracellular iron. FTH1 and FTL together form an iron storage protein complex (ferritin), preventing Fe$^{3+}$ from being oxidized to Fe$^{2+}$ by the Fenton reaction. Prominin-2 acts to form FTH1/FTL/ion complex-containing exosomes, which are then exported to the extracellular space. NCOA4 plays a role in inducing autophagic degradation of FTH1/FTL (ferritinophagy), leading to an increase in intracellular iron. ACSLs and LPCAT3 facilitate the formation of PUFA-PLs, which are susceptible to •OH-catalyzed oxidation that is mediated by ALOXs. Mitochondria serve as a main source of intracellular superoxide (O$_2^•-$), which can be reduced to H$_2$O$_2$ by dismutase. The partially reduced H$_2$O$_2$ by iron generates •OH, a process called the Fenton reaction. •OH can act to abstract hydrogen atoms from PUFA-PLs to activate lipid peroxidation and the accumulation of PUFA-PL-OOH, ultimately causing ferroptosis. •OH, hydroxyl radical; ACSL, acyl-CoA synthetase long chain family members; ALOXs, lipoxigenases; CISD1/2, CDGSH iron sulfur domain 1/2; DFO, desferoxamine; FTH1, ferritin heavy chain 1; FTL, ferritin light chain; H$_2$O$_2$, hydrogen peroxide; HO-1, heme oxygenase-1; IREB2, iron response element binding protein 2; ISCU, iron-sulfur cluster assembly enzyme; LPCAT3, lyso phospholipid acyl-transferase 3; NCOA4, nuclear receptor co-activator 4; NFS1, NFS1 cysteine desulfurase; PUFA-PL-OOH, lipid peroxides generated from polyunsaturated fatty acid-containing phospholipids; SGNI, Shuganning injection; SLC11A2, solute carrier family 11 member 2; SLC40A1, solute carrier family 40 member 1; TFRC, transferrin receptor.

Figure 1. Iron metabolism and lipid peroxides in ferroptosis. Ferroptosis is primarily triggered by iron accumulation-mediated lipid peroxidation, which is determined by key factors contributing to the import, export, and metabolism of iron and the formation of PUFA-PL-OOH. Serotransferrin-TFRC complexes load iron and facilitate its import through endosome internalization, by which iron can be released via SLC11A2. IREB2 transcriptional activity, heme/HO-1, and lactotransferrin provide additional routes of intracellular iron import. DFO acts as a scavenger of intracellular iron. FTH1 and FTL together form an iron storage protein complex (ferritin), preventing Fe$^{3+}$ from being oxidized to Fe$^{2+}$ by the Fenton reaction. Prominin-2 acts to form FTH1/FTL/ion complex-containing exosomes, which are then exported to the extracellular space. NCOA4 plays a role in inducing autophagic degradation of FTH1/FTL (ferritinophagy), leading to an increase in intracellular iron. ACSLs and LPCAT3 facilitate the formation of PUFA-PLs, which are susceptible to •OH-catalyzed oxidation that is mediated by ALOXs. Mitochondria serve as a main source of intracellular superoxide (O$_2^•-$), which can be reduced to H$_2$O$_2$ by dismutase. The partially reduced H$_2$O$_2$ by iron generates •OH, a process called the Fenton reaction. •OH can act to abstract hydrogen atoms from PUFA-PLs to activate lipid peroxidation and the accumulation of PUFA-PL-OOH, ultimately causing ferroptosis. •OH, hydroxyl radical; ACSL, acyl-CoA synthetase long chain family members; ALOXs, lipoxigenases; CISD1/2, CDGSH iron sulfur domain 1/2; DFO, desferoxamine; FTH1, ferritin heavy chain 1; FTL, ferritin light chain; H$_2$O$_2$, hydrogen peroxide; HO-1, heme oxygenase-1; IREB2, iron response element binding protein 2; ISCU, iron-sulfur cluster assembly enzyme; LPCAT3, lyso phospholipid acyl-transferase 3; NCOA4, nuclear receptor co-activator 4; NFS1, NFS1 cysteine desulfurase; PUFA-PL-OOH, lipid peroxides generated from polyunsaturated fatty acid-containing phospholipids; SGNI, Shuganning injection; SLC11A2, solute carrier family 11 member 2; SLC40A1, solute carrier family 40 member 1; TFRC, transferrin receptor.
3. Inducing Ferroptosis by Inhibiting Antioxidant Defense

There are several classes of antioxidant pathways that counteract ferroptosis. These include the glutathione (GSH)-dependent phospholipid hydroperoxidase glutathione peroxidase 4 (GPX4) pathway in the cytosol (GPX4\textsuperscript{cyto}) and mitochondria (GPX4\textsuperscript{mito}), while the GSH-independent coenzyme Q10 (CoQ10, also known as ubiquinone) pathway is underpinned by ferroptosis suppressor protein 1 (FSP1, also known as apoptosis-inducing factor mitochondrial 2 (AIF-M2)) at the plasma membrane (FSP1-CoQ10 axis) and dihydroorotate dehydrogenase (DHODH) in the mitochondrial inner membrane (DHODH-CoQ10 axis) (Figure 2) [89,90].

![Figure 2](image-url)

**Figure 2.** Antioxidant defense system that regulates ferroptosis. GSH-dependent pathways (GSH/GPX4 and MVA) and GSH-independent pathways (FSP1/CoQ10 and DHODH/CoQ10) constitute an antioxidant defense system. System xc\textsuperscript{-} composed of SLC3A2 and SLC7A11 is a cystine/glutamate antiporter that imports Cys\textsubscript{2} into cells with an equal amount of counter-transport of glutamate. The Cys\textsubscript{2} is oxidized to cysteine (Cys), which contributes to the synthesis of GSH in a reaction catalyzed by glutamate-cysteine ligase (GCL) and glutathione synthetase (GSS). Cytosolic and mitochondrial GPX4 (GPX4\textsuperscript{cyto} and GPX4\textsuperscript{mito}) eliminates ROS by converting GSH to GSSG. The MVA pathway requires HMGCR as a critical rate-limiting enzyme to generate IPP and CoQ10. IPP is involved in the synthesis of GPX4 in the presence of Se, while CoQ10 plays an important role in suppressing lipid peroxidation. FSP1 repairs lipid peroxidation on the plasma membrane by converting CoQ10 to CoQH\textsubscript{2}. By contrast, DHODH generates CoQH\textsubscript{2} by reducing CoQ10 through a uridine-synthesizing redox reaction that catalyzes DHO to OA to exert a protective effect on lipid peroxidation at the mitochondrial membrane. TYRO3 acts toward anti-ferroptosis by the PI3K/AKT/NRF2 axis to bolster the activity of GSH/GPX4. Abbreviations: BQR, brequinar sodium; circRHOT1, circular RNA RHOT1; CoQ10, coenzyme Q10; Cys, cysteine; Cys\textsubscript{2}, cystine; DHO, dihydroorotate; DHODH, dihydroorotate dehydrogenase; FSP1, ferroptosis suppressor protein 1; GCL, glutamate-cysteine ligase; GPX4, glutathione peroxidase 4; GSH, glutathione; GSK3\textbeta, glycogen synthase kinase 3 beta; GSS, glutathione synthetase; HMGCR, HMG-CoA reductase; IMM, inner membrane of mitochondria; IMS, intermembrane space; IPP, isopentenyl-D-myo-inositol; MDM2, mouse double minute 2; MVA, mevalonate; NRF2, nuclear factor, erythroid 2-like 2; OA, olate; ROS, reactive oxygen species; OMM, outer membrane of mitochondria; Se, selenium; SLC3A2, solute carrier family 3 member 2; SLC7A11, solute carrier family 7 member 11; STAT3, signal transducer and activator of transcription 3; TYRO3, tyrosine-protein kinase receptor 3.
The synthesis of GSH relies mainly on the import of cystine (Cys$_2$). System xc$^-\,$ is a cystine/glutamate antiporter widely distributed in phospholipid bilayers, acting to import Cys$_2$ into cells with a 1:1 counter-transport of glutamate [6,30] and preserve the homeostasis of the antioxidant system in cells. System xc$^-\,$ is a heterodimer composed of two subunits: solute carrier family 7 member 11 (SLC7A11) and solute carrier family 3 member 2 (SLC3A2). The Cys$_2$ taken up into cells can then be oxidized to cysteine (Cys), which is required for the synthesis of GSH in a reaction catalyzed by glutamate-cysteine ligase (GCL) and glutathione synthetase (GSS) [31]. GSH functions to reduce reactive oxygen species (ROS) and reactive nitrogen under the action of glutathione peroxidases (GPXs). Among the GPX family, GPX4 plays a critical role in regulating the occurrence of ferroptosis. GPX4 can convert GSH into oxidized glutathione (GSSG) and reduce cytoxic lipid peroxides (L-OOH) to the corresponding alcohols (L-OH), thereby inhibiting the formation of lipid peroxides (Figure 2). RSL3 and ML162 can serve as GPX4 inhibitors to promote cell ferroptosis [90]. The mevalonate (MVA) pathway counteracts ferroptosis by generating anti-ferroptotic biomolecules, including isopentenyl-pyrophosphate (IPP) and CoQ10. The synthetic processes of the two molecules require a rate-limiting enzyme, HMG-CoA reductase (HMGR), which is also an inhibitory target of statins (a class of cholesterol-lowering drugs) [35]. IPP acts to stabilize selenocysteine tRNA, which is required for the synthesis of GPX4 [91]. Concerning the GPX4-independent CoQ10 pathway, Bersuker et al. first identified that FSP-1, a flavoprotein formerly known as AIF-M2 (apoptosis-inducing factor mitochondrial 2), exhibits a protective effect against ferroptosis, as induced by GPX4 deletion [92]. At the plasma membrane, FSP-1 acts as an oxidoreductase that reduces CoQ10 to generate CoQH2 (also known as ubiquinol) which can repair lipid peroxides [93]. More recently, Mao et al. reported that the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) acts to coordinate with GPX4$_{\text{mito}}$ to prevent ferroptosis by detoxifying accumulated lipid peroxides in mitochondria [89]. DHODH has been recognized as an iron-containing flavin-dependent enzyme, and is involved in the de novo synthesis of pyrimidines in mitochondria [94]. Further study revealed that DHODH generates CoQH2 by reducing CoQ10 through a uridine-synthesizing redox reaction that catalyzed dihydroorotate to orotate [89]. DHODH inhibitors have previously been used in the treatment of autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis [90]. The findings of Mao et al. regarding the role of DHODH in ferroptosis could exploit the synthetic lethal (SL) concept, by which DHODH inhibitors exert an anticancer effect in GPX4$_{\text{low}}$ cells; meanwhile, the combination of DHODH inhibitors with sulfasalazine (an inhibitor of system xc$^-\,$) can be applied to GPX4$_{\text{high}}$ cells [89].

Wen et al. reported that an active compound from the medicinal herbal licorice, 18-β-glycyrrhetinic acid, could induce ferroptosis in TNBC cells by downregulating the expression of SLC7A11 of system xc$^-\,$, the GSH level, the GPX activity, and upregulating the ROS and lipid peroxidation [54]. Sun et al. reported that lidocaine exerts a pro-ferroptosis effect in BC and ovarian cancer by targeting the miR-382-5p/SLC7A11 axis [51]. Zhang et al. revealed that microRNA(miR)-106a-5p promotes ferroptosis via the suppression of the signal transducer and activator of transcription 3 (STAT3), whereby SLC7A11 levels are downregulated in BC cells [52]. Circular RNA RHOST1 (circRHOST1) has been identified as a ferroptosis inhibitor by sponging miR-106-5a [52]. Liu et al. revealed a nitrosoxazole-containing compound (3d) that can effectively induce ferroptosis of MCF-7 both in vitro and in vivo [60]. As a GPX4/mouse double minute 2 (MDM2) dual inhibitor, 3d presents dual inhibitory activities with the suppression of GPX4 levels and MDM2-mediated degradation of p53 [60]. Wu et al. demonstrated that overexpression of glycogen synthase kinase-3β (GSK-3β) sensitizes erastin-induced ferroptosis by inhibition of a nuclear factor, erythroid 2-like 2 (NFE2L2, also known as NRF2), thereby downregulating GPX4 levels [56]. It is worth noting that upregulation of NRF2 can lead to ferroptosis resistance. Qiao et al. demonstrated that upregulated NRF2 contributed to BET inhibitor-induced ferroptosis in BC cancer cells [95]. siRNA-based knockdown of nuclear receptor subfamily 5 group A member 2 (NR5A2) and nuclear receptor coactivator 3 (NCOA3) caused a decrease in NRF2
expression levels, thereby counteracting BET inhibitor-induced ferroptosis. Verma et al. demonstrated a high-throughput screen reliant on the concept of SL which reported that a combination of BET inhibitor JQ1 and proteasome inhibitor bortezomib (BTZ) (JQ1+BTZ) considerably induced TNBC ferroptosis by inhibiting GPX4 expression levels [55]. Ding et al. demonstrated that DMOCPTL, a derivative of the natural product parthenolide, exhibited a pro-ferroptosis effect on TNBC cell growth by inducing GPX4 ubiquitination [59]. Lee et al. reported that erastin induces TNBC cell ferroptosis by inhibiting system xc− and depleting GPX4 levels, despite the resistance against oxidative stress [50]. Jiang et al. reported that tyrosine-protein kinase receptor 3 (TYRO3) plays a negative role on tumor ferroptosis, and induces resistance to anti-PD1/PD-L1 treatment [32]. TYRO3 overexpression activates the PI3K/AKT pathway to increase NRF2 transcriptional activity that is responsible for the transcription of ferroptosis-inhibitory genes, including SLC3A2, SLC7A11, FTL, FTH1, GPX4, SLC40A1, and biliverdin reductase A/B (BLVRA/B) [32]. Further study showed that the TYRO3 inhibitor, LDC1267, can elicit ferroptosis and potentiate immunotherapy in a 4T1 BC cell inoculation mouse model [32]. Song et al. developed acidity-activatable dynamic nanoparticles encapsulating RSL-3 to target GPX4, unveiling a strategy for ferroptosis-inducing tumor specific delivery. This nanoparticle approach acts to potentiate immunotherapy by recruiting tumor-infiltrating T lymphocytes for interferon gamma (IFNγ) secretion [57]. Hou et al. demonstrated that metformin induces TNBC cell ferroptosis via an upregulation of miR-324-3p, by which GPX4 expression is inhibited by targeting its 3′UTR [58]. In addition, Yang et al. revealed that antidiabetic metformin acts as an anti-BC agent by reducing the protein stability of SLC7A11 of system xc-, increasing intracellular Fe2+ and lipid ROS levels [53]. Furthermore, the combination of metformin with sulfasalazine, the system xc- inhibitor, can cause a potentiation effect to induce ferroptosis [53]. Concerning the blocking of the MVA pathway as a targeting strategy, two clinical trials involving BC patients have indicated that fluvastatin and atorvastatin might have antiproliferative effects in tumors overexpressing HMGCR [63,64]. Hubackova et al. reported that the DHODH inhibitor leflunomide exerts a potentiation effect on inducing TNBC cell death in vitro, and tumor growth in vivo, when combined with a checkpoint kinase 1 (Chk1) inhibitor [61]. Mohama Fairus et al. demonstrated that DHODH inhibitors, including brequinar sodium (BQR), leflunomide, and 4SC-101 provoked ROS generation and ATP depletion by a p53-mediated route, thereby suppressing BC cell proliferation [62]. The molecular basis and drugs targeting the antioxidant defense systems of ferroptosis in BC, including GPX4/GSH, MVA, FSP1-CoQ10, and DHODH-CoQ10, are illustrated in Figure 2. The current therapeutic approaches for targeting these pathways are summarized in Table 2.

4. Conclusions

There exist several tumor subtypes of BC, which are highly heterogenous malignancies, and considered particularly challenging to treat due to their resilience to standard therapeutic agents and high probability of recurrence. The past five years have seen a growing number of studies focused on the role of ferroptosis in BC. These investigations have further clarified our understanding of ferroptosis, which involves the integration of a highly organized system that regulates iron metabolism, lipid peroxidation, and anti-oxidant defense, relying on specialized mechanisms in the plasma membrane, mitochondria, and cytosol. The accumulated knowledge has been exploited to further improve the prevention and treatment of this disease. For instance, mounting preclinical evidence indicates that the induction of ferroptosis may be an effective therapeutic strategy to prevent acquired resistance to several cancer therapies, and to exert a potentiation effect on immunotherapy [32,42,49]. More importantly, clinical trials that apply ferroptosis-inducing agents to patients with BC are ongoing. As such, it is inevitable that continuing research in this field will further elucidate the physiological and pathological roles of ferroptosis, leading to the development of translational anticancer strategies. Research into biomarkers to precisely
trace ferroptosis in patients with cancer, and the development and subsequent application of novel ferroptosis-based therapies will be of critical importance in the next few years.

Author Contributions: Conceptualization, H.-Y.L. and H.-W.H.; methodology, Y.-H.C.; software, H.-W.H.; validation, C.-J.W. and P.-Y.C.; formal analysis, H.-W.H.; investigation, H.-Y.L. and Y.-H.C.; resources, C.-J.W. and P.-Y.C.; data curation, H.-W.H.; writing—original draft preparation, H.-Y.L.; writing—review and editing, C.-J.W. and P.-Y.C.; visualization, H.-W.H. and Y.-H.C.; supervision, P.-Y.C.; project administration, H.-Y.L., H.-W.H. and P.-Y.C.; funding acquisition, H.-W.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Ministry of Science and Technology, Taiwan (MOST 106-2314-B-442-001-MY3, MOST 109-2314-B-442-001-and MOST 109-2314-B-075B-002), National Health Research Institutes, Taiwan (NHRI-109BCCO-MF-202015-01), and Show Chwan Memorial Hospital, Taiwan (SRD-1040305, SRD-110016 and SRD-110017).

Acknowledgments: The authors would like to thank James Waddell for his assistance with the proofreading of this article.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef]
2. Liu, J.; Shen, J.X.; Wen, X.F.; Guo, Y.X.; Zhang, G.J. Targeting Notch degradation system provides promise for breast cancer therapeutics. Crit. Rev. Oncol. Hematol. 2016, 104, 21–29. [CrossRef]
3. Ono, M.; Ogilvie, J.M.; Wilson, J.S.; Green, H.J.; Chambers, S.K.; Ownsworth, T.; Shum, D.H. A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Front. Oncol. 2015, 5, 59. [CrossRef] [PubMed]
4. El Ansari, R.; McIntyre, A.; Craze, M.L.; Ellis, I.O.; Rakha, E.A.; Green, A.R. Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. Histopathology 2018, 72, 183–190. [CrossRef] [PubMed]
5. Fang, Y.; Tian, S.; Pan, Y.; Li, W.; Wang, Q.; Tang, Y.; Yu, T.; Wu, X.; Shi, Y.; Ma, P.; et al. Pyroptosis: A new frontier in cancer. Biomed. Pharmacother 2020, 121, 109595. [CrossRef] [PubMed]
6. Li, J.; Cao, F.; Yin, H.L.; Huang, Z.J.; Lin, Z.T.; Mao, N.; Sun, B.; Wang, G. Ferroptosis: Past, present and future. Cell Death Dis. 2020, 11, 88. [CrossRef]
7. Gudipaty, S.A.; Conner, C.M.; Rosenblatt, J.; Montell, D.J. Unconventional Ways to Live and Die: Cell Death and Survival in Development, Homeostasis, and Disease. Annu. Rev. Cell Dev. Biol. 2018, 34, 311–332. [CrossRef]
8. Khan, I.; Yousif, A.; Chesnokov, M.; Hong, L.; Chefetz, I. A decade of cell death studies: Breathing new life into necroptosis. Pharmacol Ther. 2021, 220, 107717. [CrossRef] [PubMed]
9. Carneiro, B.A.; El-Deiry, W.S. Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Oncol. 2020, 17, 395–417. [CrossRef] [PubMed]
10. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646–674. [CrossRef] [PubMed]
11. Fulda, S.; Debatin, K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25, 4798–4811. [CrossRef]
12. Wang, X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001, 15, 2922–2933. [CrossRef]
13. Puthalakath, H.; Strasser, A. Keeping killers on a tight leash: Transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 2002, 9, 505–512. [CrossRef]
14. Hetz, C.; Zhang, K.; Kaufman, R.J. Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 2020, 21, 421–438. [CrossRef] [PubMed]
15. Tang, D.; Kang, R.; Berghe, T.V.; Vandenabeele, P.; Kroemer, G. The molecular machinery of regulated cell death. Cell Res. 2019, 29, 347–364. [CrossRef] [PubMed]
16. Du, T.; Gao, J.; Li, P.; Wang, Y.; Qi, Q.; Liu, X.; Li, J.; Wang, C.; Du, L. Pyroptosis, metabolism, and tumor immune microenvironment. Clin. Transl. Med. 2021, 11, e492. [CrossRef] [PubMed]
17. Kayagaki, N.; Stowe, I.B.; Lee, B.L.; O’Rourke, K.; Anderson, K.; Warming, S.; Cuellar, T.; Haley, B.; Roose-Girma, M.; Plung, Q.T.; et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 2015, 526, 666–671. [CrossRef]
18. Man, S.M.; Kanneganti, T.D. Gasdermin D: The long-awaited executioner of pyroptosis. Cell Res. 2015, 25, 1183–1184. [CrossRef]
19. Shi, J.; Zhao, Y.; Wang, K.; Shi, X.; Wang, Y.; Huang, H.; Zhuang, Y.; Cai, T.; Wang, F.; Shao, F. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 2015, 526, 660–665. [CrossRef] [PubMed]
20. Wang, Y.; Gao, W.; Shi, X.; Ding, J.; Liu, W.; He, H.; Wang, K.; Shao, F. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 2017, 547, 99–103. [CrossRef]
21. Zhang, Z.; Zhang, Y.; Xia, S.; Kong, Q.; Li, S.; Liu, X.; Junqueira, C.; Meza-Sosa, K.F.; Mok, T.M.Y.; Ansara, J.; et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 2020, 579, 415–420. [CrossRef]
22. Tang, R.; Xu, J.; Zhang, B.; Liu, J.; Liang, C.; Hua, J.; Meng, Q.; Yu, X.; Shi, S. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J. Hematol. Oncol. 2020, 13, 110. [CrossRef] [PubMed]

23. Efferth, T. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. Semin. Cancer Biol. 2017, 46, 65–83. [CrossRef] [PubMed]

24. Zhang, L.X.; Liu, Z.N.; Ye, J.; Sha, M.; Qian, H.; Bu, X.H.; Luan, Z.Y.; Xu, X.L.; Huang, A.H.; Yuan, D.L.; et al. Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression. Cell Biol. Int. 2014, 38, 639–646. [CrossRef] [PubMed]

25. Cui, C.; Feng, H.; Shi, X.; Wang, Y.; Zeng, F.; Liu, J.; Han, Z.; Fu, J.; Fu, Z.; Tong. Artesunate down-regulates immunosuppression from colorectal cancer Colon26 and RKO cells in vitro by decreasing transforming growth factor beta1 and interleukin-10. Int. Immunopharmacol. 2015, 27, 110–121. [CrossRef] [PubMed]

26. Qian, P.; Zhang, Y.W.; Zhou, Z.H.; Liu, J.Q.; Yue, S.Y.; Guo, X.L.; Sun, L.Q.; Lv, X.T.; Chen, J.Q. Artesunate enhances gammadelta T-cell-mediated antitumor activity through augmenting gammadelta T-cell function and reversing immune escape of HepG2 cells. Immunopharmacol. Immunotoxicol. 2018, 40, 107–116. [CrossRef] [PubMed]

27. Duong, B.H.; Onizawa, M.; Oses-Prieto, J.A.; Advincula, R.; Burlingame, A.; Malynn, B.A.; Ma, A. A20 restricts ubiquitination of pro-interleukin-1beta protein complexes and suppresses NLRP3 inflammasome activity. Immunity 2015, 42, 55–67. [CrossRef] [PubMed]

28. Guo, J.; Xu, B.; Han, Q.; Zhou, H.; Xia, Y.; Gong, C.; Dai, X.; Li, Z.; Wu, G. Ferroptosis: A Novel Anti-tumor Action for Cisplatin. [CrossRef] [PubMed]

29. Zhang, C.C.; Li, C.G.; Wang, Y.F.; Xu, L.H.; He, X.H.; Zeng, Q.Z.; Zeng, C.Y.; Mai, F.Y.; Hu, B.; Ouyang, D.Y. Chemotherapeutic effects of artemisinin on human cervical cancer cells in vitro. Oxid. Med. Cell Longev. 2011, 2011, 3161. [CrossRef] [PubMed]

30. Dixon, S.J.; Lemberg, K.M.; Lampricht, M.R.; Skouta, R.; Zaitsev, E.M.; Gleason, C.E.; Patel, D.N.; Bauer, A.J.; Cantley, A.M.; Yang, W.S.; et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012, 149, 1060–1072. [CrossRef] [PubMed]

31. Chen, X.; Kang, R.; Kroemer, G.; Tang, D. Broadening horizons: The role of ferroptosis in cancer. Nat. Rev. Clin. Oncol. 2021, 18, 205–218. [CrossRef] [PubMed]

32. Jiang, Z.; Lim, S.O.; Yan, M.; Hsu, J.L.; Yao, J.; Wei, Y.; Chang, S.S.; Yamaguchi, H.; Lee, H.H.; Ke, B.; et al. TYRO3 induces autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. J. Cell Death 2020, 9, 1605–1619. [CrossRef] [PubMed]

33. Friedmann Angeli, J.P.; Krysko, D.V.; Conrad, M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer 2019, 19, 405–419. [CrossRef] [PubMed]

34. Wang, K.J.; Meng, X.Y.; Chen, J.F.; Wang, K.Y.; Zhou, C.; Yu, R.; Ma, Q. Emodin Induced Necroptosis and Inhibited Glycolysis in HepG2 Cells. Oxid. Med. Cell Longev. 2020, 2020, 6235–6245. [CrossRef] [PubMed]

35. Antoniak, M.A.; Pazik, R.; Bazylinska, U.; Wiwatowski, K.; Tomaszweska, A.; Kulpa-Greszta, M.; Adamczyk-Grochala, J.; Wnuk, M.; Mackowski, S.; Lewinska, A.; et al. Multimodal polymer encapsulated CdSe/Fe3O4 nanoplatform with improved biocompatibility for two-photon and temperature stimulated bioapplications. Mater. Sci. Eng. C Mater. Biol. Appl. 2021, 110–121. [CrossRef] [PubMed]

36. Nagpal, A.; Redvers, R.P.; Ling, X.; Ayton, S.; Fuentes, M.; Tavancheh, E.; Diaz, I.; Lalan, A.; Loi, S.; David, S.; et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+) breast cancer metastasis. Breast Cancer Res. 2019, 21, 94. [CrossRef] [PubMed]

37. Nieto, C.; Vega, M.A.; Martin Del Valle, E.M. Tailored-Made Polydopamine Nanoparticles to Induce Ferroptosis in Breast Cancer Cells in Combination with Chemotherapy. Int. J. Mol. Sci. 2021, 22, 3161. [CrossRef] [PubMed]

38. Bai, F.; Morcos, F.; Sohn, Y.S.; Darash-Yahana, M.; Rezende, C.O.; Lipper, C.H.; Paddock, M.L.; Song, L.; Luo, Y.; Holt, S.H.; et al. The Fe-S cluster-containing NEET proteins mitoNEET and NAF-1 as chemotherapeutic targets in breast cancer. Proc. Natl. Acad. Sci. USA 2015, 112, 3698–3703. [CrossRef] [PubMed]
69. Fisher, J.; Devraj, K.; Ingram, J.; Slagle-Webb, B.; Madhankumar, A.B.; Liu, X.; Klinger, M.; Simpson, I.A.; Connor, J.R. Ferritin: A novel mechanism for delivery of iron to the brain and other organs. Am. J. Physiol. Cell Physiol. 2007, 293, C641–C649. [CrossRef]

70. Brown, C.W.; Amante, J.J.; Chhoy, P.; Elaimy, A.L.; Liu, H.; Zhu, L.J.; Baer, C.E.; Dixon, S.J.; Mercurio, A.M. Prominin2 Drives Ferroptosis Resistance by Stimulating Iron Export. Dev. Cell 2019, 51, 575–586.e4. [CrossRef]

71. Gammella, E.; Recalcati, S.; Rybinska, I.; Buratti, P.; Cairo, G. Iron-induced damage in cardiomyopathy: Oxidative-dependent and independent mechanisms. Oxid. Med. Cell. Longev. 2015, 2015, 230812. [CrossRef]

72. Gao, M.; Monian, P.; Pan, Q.; Zhang, W.; Jiang, J. Ferroptosis is an autophagic cell death process. Cell Res. 2016, 26, 1021–1032. [CrossRef]

73. Hou, W.; Xie, Y.; Song, X.; Sun, X.; Lotze, M.T.; Zeh, H.J.; Kang, R.; Tang, D. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 2016, 12, 1425–1428. [CrossRef]

74. Alvarez, S.W.; Sviderskiy, V.O.; Terzi, E.M.; Papagiannakopoulos, T.; Moreira, A.L.; Adams, S.; Sabatini, D.M.; Birsoy, K.; Possemato, R. NPS1 undergoes selective positive selection in lung tumours and protects cells from ferroptosis. Nature 2017, 551, 639–643. [CrossRef] [PubMed]

75. Du, J.; Wang, T.; Li, Y.; Zhou, Y.; Wang, X.; Yu, X.; Ren, X.; An, Y.; Wu, Y.; Sun, W.; et al. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic. Biol. Med. 2019, 131, 356–369. [CrossRef] [PubMed]

76. Kim, E.H.; Shin, D.; Lee, J.; Jung, A.R.; Roh, J.L. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer. Sci. Transl. Med. 2018, 10, 180–190. [CrossRef] [PubMed]

77. Yuan, H.; Li, X.; Zhang, X.; Kang, R.; Tang, D. CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochem. Biophys. Res. Commun. 2016, 478, 834–844. [CrossRef]

78. Stockwell, B.R.; Friedmann Angeli, J.P.; Bayir, H.; Bush, A.L.; Conrad, M.; Dixon, S.J.; Fulda, S.; Gascon, S.; Hatzios, S.K.; Kagan, V.E.; et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 2017, 171, 273–285. [CrossRef] [PubMed]

79. Yang, W.S.; Kim, K.J.; Gaschler, M.M.; Patel, M.; Shcepino, M.S.; Stockwell, B.R. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl. Acad. Sci. USA 2016, 113, E4966–E4975. [CrossRef]

80. Yang, W.S.; Stockwell, B.R. Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol. 2016, 26, 165–176. [CrossRef]

81. Dixon, S.J.; Winter, G.E.; Musavi, L.S.; Lee, E.D.; Snijder, B.; Rebsamen, M.; Superti-Furga, G.; Stockwell, B.R. Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. ACS Chem. Biol. 2015, 10, 1604–1609. [CrossRef] [PubMed]

82. Doll, S.; Proneth, B.; Tyurina, Y.Y.; Panzilius, E.; Kobayashi, S.; Ingold, I.; Irmler, M.; Beckers, J.; Aichler, M.; Walch, A.; et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 2017, 13, 91–98. [CrossRef] [PubMed]

83. Kagan, V.E.; Mao, G.; Qu, F.; Angeli, J.P.; Doll, S.; Croix, C.S.; Dar, H.H.; Liu, B.; Tyurin, V.A.; Ritov, V.B.; et al. Oxidized arachidonic and arachidonic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 2017, 13, 81–90. [CrossRef] [PubMed]

84. Yuan, H.; Li, X.; Zhang, X.; Kang, R.; Tang, D. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem. Biophys. Res. Commun. 2016, 478, 1338–1343. [CrossRef] [PubMed]

85. Eling, N.; Reuter, L.; Hazin, J.; Hamacher-Brady, A.; Brady, N.R. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2015, 2, 517–532. [CrossRef]

86. Lin, R.; Zhang, Z.; Chen, L.; Zhou, Y.; Zou, P.; Feng, C.; Wang, L.; Liang, G. Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells. Cancer Lett. 2016, 381, 165–175. [CrossRef]

87. Ooko, E.; Saeed, M.E.; Kadioglu, O.; Sarvi, S.; Colak, M.; Elmasaoudi, K.; Janah, R.; Greten, H.J.; Efferth, T. Artemisinin derivatives induce breast cancer resistance to BET inhibitor by upregulating NRF2 to attenuate ferroptosis. Biochem. Biophys. Res. Commun. 2016, 457, 4573–4579. [CrossRef] [PubMed]

88. Scheel, C.H.; et al. FSP1 is a glutathione-independent ferroptosis suppressor. J. Biol. Chem. 2017, 292, 10439–10451. [CrossRef]

89. Gammella, E.; Recalcati, S.; Rybinska, I.; Buratti, P.; Cairo, G. Iron-induced damage in cardiomyopathy: Oxidative-dependent and independent mechanisms. Oxid. Med. Cell Longev. 2015, 2015, 230812. [CrossRef] [PubMed]

90. Wang, F.; Min, J. DHODH tangoing with GPX4 on the ferroptotic stage. Signal. Transduct. Target. Ther. 2021, 6, 244. [CrossRef] [PubMed]

91. Warner, G.J.; Berry, M.J.; Moustafa, M.E.; Carlson, B.A.; Hatfield, D.L.; Faust, J.R. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]Sec lacking isopentenyladenosine. J. Biol. Chem. 2000, 275, 28110–28119. [CrossRef]

92. Bersuker, K.; Hendricks, J.M.; Li, Z.; Magtanong, L.; Ford, B.; Tang, P.H.; Roberts, M.A.; Tong, B.; Maimone, T.J.; Zoncu, R.; et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 2019, 575, 688–692. [CrossRef] [PubMed]

93. Doll, S.; Freitas, F.P.; Shah, R.; Aldrovandi, M.; da Silva, M.C.; Ingold, I.; Goya Grocin, A.; Xavier da Silva, T.N.; Panzilius, E.; Scheel, C.H.; et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 2019, 575, 693–698. [CrossRef] [PubMed]

94. Garcia-Bermudez, J.; Birsoy, K. A mitochondrial gatekeeper that helps cells escape death by ferroptosis. Nature 2021, 593, 514–515. [CrossRef]

95. Qiao, J.; Chen, Y.; Yi, M.; Jin, H.; Huang, T.; Liu, L.; Gong, L.; Wang, L.; Wang, Q.; Zou, Z. NRSF2 synergizes with NCOA3 to induce breast cancer resistance to BET inhibitor by upregulating NRF2 to attenuate ferroptosis. Biochem. Biophys. Res. Commun. 2020, 530, 402–409. [CrossRef]